Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Chimeric antigen receptor T-cell (CAR-T) therapy has transformed hematological malignancy treatment.
• CD19-targeted CAR-T therapy offers substantial responses in relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
• Primary resistance and long-term disease control failure limit CAR-T cell therapy's utility.

Purpose of the Study:

• To comprehensively review resistance mechanisms against CAR-T therapy in DLBCL.
• To explore multifaceted resistance pathways beyond CD19 loss.
• To identify novel therapeutic targets and guide next-generation CAR-T cell engineering.

Main Methods:

• Mechanistic insights from four interconnected dimensions of resistance were explored.
• Analysis of molecular alterations, cell-intrinsic factors, tumor microenvironment, and innate resistance pathways.
• Literature review and synthesis of current knowledge on CAR-T resistance.

Main Results:

• Resistance mechanisms include tumor-associated CD19 expression loss.
• Cell-intrinsic factors lead to CAR-T cell differentiation arrest and functional exhaustion.
• Immunomodulatory escape programs and innate tumor cell resistance pathways contribute to treatment failure.

Conclusions:

• Elucidating resistance mechanisms provides foundations for novel therapeutic targets.
• Understanding resistance is crucial for engineering next-generation CAR-T cells.
• Improved CAR-T cell design promises enhanced anti-tumor potency and reduced toxicity for diverse malignancies.